|
Temazepam
(N=9) |
Placebo
(n=9) |
Gender (N)
Male
Female |
|
|
8 (89%) |
8 (89%) |
1 (11%) |
1 (11%) |
Ethnicity (N)
Caucasian
Hispanic
African American
Unknown |
|
|
4 (44%) |
4 (44%) |
4 (44%) |
4 (44%) |
1 (6%) |
0 (0%) |
0 (0%) |
1 (6%) |
Age (yrs) |
36.22±7.60 |
33.33±7.92 |
Education (yrs) |
12.44±0.73 |
11.67±1.50 |
Verbal IQ |
110.05±7.29 |
110.75±3.33 |
METH Drug Use |
|
|
Years of use |
12.67±8.57 |
12.22±6.57 |
^ Recent use |
20.00±9.30 |
16.67±8.63 |
Grams/week |
9.54±9.08 |
9.54±9.08 |
Days Abstinent |
5.67±1.12 |
6.67±1.23 |
Nicotine Use |
8 (89%) |
7 (78%) |
Sleep Quality |
|
|
PSQI |
8.44±4.67 |
4.44±2.83* |
ESS |
9.11±6.57 |
8.78±2.49 |
1 Same subject population as reported in Mahoney, 2011
^ Recent use indicates number of days of use of primary drug in the 30 days preceding interview.
*p < 0.05Age, Education, Years of use, and Recent use, Grams/week, Amount Spent/week, Days Abstinent, PSQI, ESS reflect mean ± S. D. |
